|Mr. Paul J. Diaz||CEO, Pres & Director||2.92M||N/A||1962|
|Mr. R. Bryan Riggsbee||Exec. VP, CFO & Treasurer||934.49k||N/A||1971|
|Ms. Nicole Lambert||COO & Pres of Myriad Genetic Laboratories||825.23k||N/A||1974|
|Mr. Mark S. Verratti||Chief Commercial Officer||723.29k||N/A||1968|
|Dr. Kevin Richard Haas||Chief Technology Officer||N/A||N/A||1986|
|Dr. Dale Muzzey Ph.D.||Chief Scientific Officer||N/A||N/A||1980|
|Mr. Scott Gleason||Sr. VP of Investor Relations||N/A||N/A||1979|
|Mr. Nathan Smith||Sr. VP of Investor Relations & Treasury||N/A||N/A||N/A|
|Dr. Clivetty Martinez||Chief Compliance Officer||N/A||N/A||N/A|
|Ms. Pamela Wong||Chief Legal Officer||N/A||N/A||1968|
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 5. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 6; Compensation: 6.